Astagraf Xl

Vitiligo, Pyoderma Gangrenosum, Kidney Transplantation + 12 more

Treatment

3 FDA approvals

20 Active Studies for Astagraf Xl

Treatment for

Vitiligo

What is Astagraf Xl

TacrolimusThe Generic name of this drug

Treatment SummaryTacrolimus (also known as FK-506 or Fujimycin) is an immunosuppressive drug used to reduce the activity of the patient's immune system after an organ transplant. It is also used to treat severe atopic dermatitis, uveitis after bone marrow transplants, and vitiligo. Tacrolimus was discovered in 1984 from a Japanese soil sample and works by binding to FKBP-12, which prevents calcineurin from activating T-lymphocytes and IL-2 transcription.

Prografis the brand name

Astagraf Xl Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prograf

Tacrolimus

1994

138

Approved as Treatment by the FDA

Tacrolimus, also called Prograf, is approved by the FDA for 3 uses such as Kidney Transplantation and Kidney .

Kidney Transplantation

Kidney

Immunosuppressive Treatment

Effectiveness

How Astagraf Xl Affects PatientsTacrolimus works by blocking the activity of proteins that help activate the immune system. This helps decrease the risk of organ rejection and has also been shown to be effective for treating eczema. It doesn't work as powerfully as topical steroids, but it can be used directly on the face without causing thinning of the skin. On other parts of the body, topical steroids are usually a better choice.

How Astagraf Xl works in the bodyThe exact way tacrolimus works to treat atopic dermatitis is unknown, but there are some observed effects. Tacrolimus works by blocking an intracellular protein called FKBP-12, which prevents the formation of a complex that initiates gene transcription for making lymphokines. Tacrolimus also prevents the transcription of genes that produce inflammatory molecules like IL-3, IL-4, IL-5, GM-CSF, and TNF-. Additionally, tacrolimus can stop the release of pre-formed mediators from skin mast cells and basophils, as well as downregulating

When to interrupt dosage

The suggested measure of Astagraf Xl is contingent upon the diagnosed situation, including Vitiligo, Rejection; Transplant, Kidney and Pyoderma Gangrenosum. The amount fluctuates based on the method of delivery (e.g. Capsule, gelatin coated - Oral or Topical) outlined in the table beneath.

Condition

Dosage

Administration

Pyoderma Gangrenosum

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Rheumatoid Arthritis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Chronic Graft Versus Host Disease

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Vitiligo

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Prophylaxis against heart transplant rejection

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Lung

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunocompromised

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney Transplantation

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Oral Lichen Planus

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Liver

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunosuppressive Treatment

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Psoriasis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Warnings

Astagraf Xl has one contraindication, so it should be avoided when confronted with any of the conditions in the ensuing table.Astagraf Xl Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Tacrolimus may interact with Pulse Frequency

There are 20 known major drug interactions with Astagraf Xl.

Common Astagraf Xl Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tacrolimus.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Tacrolimus.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.

Bacillus calmette-guerin substrain russian BCG-I live antigen

Major

The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Tacrolimus.

Astagraf Xl Toxicity & Overdose RiskTaking too much of this drug can cause blurry vision, kidney and liver issues, seizures, trembling, high blood pressure, low magnesium levels, diabetes, high potassium levels, itching, difficulty sleeping, and confusion. The toxic dose in rats is 134-194mg/kg.

image of a doctor in a lab doing drug, clinical research

Astagraf Xl Novel Uses: Which Conditions Have a Clinical Trial Featuring Astagraf Xl?

147 active trials are currently being conducted to assess the potency of Astagraf Xl in providing relief for Oral Lichen Planus, Pyoderma Gangrenosum and refractory Rheumatoid arthritis.

Condition

Clinical Trials

Trial Phases

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Rheumatoid Arthritis

61 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Psoriasis

0 Actively Recruiting

Chronic Graft Versus Host Disease

29 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Vitiligo

18 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Pyoderma Gangrenosum

4 Actively Recruiting

Phase 2, Early Phase 1, Phase 3

Lung

0 Actively Recruiting

Oral Lichen Planus

1 Actively Recruiting

Phase 2

Dermatitis, Atopic

0 Actively Recruiting

Kidney Transplantation

0 Actively Recruiting

Liver

0 Actively Recruiting

Immunosuppressive Treatment

0 Actively Recruiting

Immunocompromised

4 Actively Recruiting

Phase 3, Not Applicable, Phase 1

Dermatitis, Atopic

0 Actively Recruiting

Kidney

0 Actively Recruiting

Astagraf Xl Reviews: What are patients saying about Astagraf Xl?

5Patient Review

4/28/2015

Astagraf Xl for Prevent Kidney Transplant Rejection

The side effects were really concerning me, but after doing some research I feel a lot better about taking the medication.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about astagraf xl

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you crush extended-release tablets?

"There are some extended-release products that can be crushed or chewed, but the majority should not be. Apr 1, 2009"

Answered by AI

What is ASTAGRAF XL used for?

"ASTAGRAF XL is a prescription medicine that helps prevent organ rejection in people who have had a kidney transplant. ASTAGRAF XL is an extended-release capsule, and is not the same as tacrolimus immediate-release capsules, tacrolimus for oral suspension, or tacrolimus extended-release tablets."

Answered by AI

What happens if tacrolimus level is high?

"You should not take more or less of the medicine than your doctor ordered, and you should not take it more often than they said. If you use too much of the medicine, it will increase the chance for side effects. If you use too little, it may cause your transplanted organ to be rejected. The medicine comes with a Medication Guide or a patient information insert with patient instructions."

Answered by AI

What causes tacrolimus levels to rise?

"The pharmacokinetics of tacrolimus are influenced by many factors which can result in elevated concentrations, including genetic variability, acute infections, liver dysfunction, and interacting medications."

Answered by AI

Clinical Trials for Astagraf Xl

Image of University of Colorado in Aurora, United States.

SBT777101 for Rheumatoid Arthritis

This trial is testing a new treatment called SBT777101 for people with rheumatoid arthritis. The study will look at whether it is safe and how it affects the participants. The treatment will be

University of Colorado (+4 Sites)Mark Eisner, MDSonoma Biotherapeutics, Inc.

Image of Marvel Clinical Research in Huntington Beach, United States.

Placebo +2 More for Vitiligo

Huntington Beach, CA

This trial is studying a medication called ritlecitinib to see how safe and effective it is in treating non-segmental vitiligo, a skin disorder characterized by white patches on the skin

Marvel Clinical Research (+10 Sites)Pfizer CT.gov Call CenterPfizer

Image of University of Miami in Miami, United States.

Horizons Group for Quality of Life

This trial tests if a group therapy program can improve quality of life for people with GvHD.

University of MiamiLara Traeger, PhD

Image of UNC Dermatology and Skin Cancer Center in Chapel Hill, United States.

Baricitinib for Oral Lichen Planus

Chapel Hill, NC

This trial is testing baricitinib to evaluate its effectiveness & safety in treating Oral Lichen Planus & its impact on quality of life.

UNC Dermatology and Skin Cancer CenterDonna Culton, MD, PhDEli Lilly and Company

Have you considered Astagraf Xl clinical trials? We made a collection of clinical trials featuring Astagraf Xl, we think they might fit your search criteria.

Explore trials for Astagraf Xl

Image of Michigan Center for Research Company /ID# 260069 in Clarkston, United States.

Upadacitinib +1 More for Vitiligo

This trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.

Waitlist Available

Michigan Center for Research Company /ID# 260069 (+34 Sites)ABBVIE INC.AbbVie

Image of Research Site in Montréal, Canada.

AZD6912 Dose 1 for Rheumatoid Arthritis

Montréal, Canada

This trial will test the safety and effects of increasing doses of AZD6912 given as a single injection under the skin to healthy volunteers.

Research SiteAstraZeneca

Image of University of Alabama At Birmingham Hospital-Whitaker Clinic in Birmingham, United States.

Povorcitinib for Vitiligo

This trial tests a new drug to treat vitiligo, a skin disorder that causes discoloration.

University of Alabama At Birmingham Hospital-Whitaker Clinic (+37 Sites)Incyte Medical MonitorIncyte Corporation

Image of Cahaba Dermatology in Hoover, United States.

Povorcitinib for Vitiligo

This trial tests if a new drug is safe and effective to treat vitiligo, a skin condition.

Cahaba Dermatology (+41 Sites)Incyte Medical MonitorIncyte Corporation

Have you considered Astagraf Xl clinical trials? We made a collection of clinical trials featuring Astagraf Xl, we think they might fit your search criteria.

Explore trials for Astagraf Xl

Image of Clinuvel investigational site in Los Angeles, United States.

SCENESSE + NB-UVB Light for Vitiligo

Los Angeles, CA

This trial will investigate if a drug and light therapy are better than light therapy alone for treating vitiligo on the body and face.

Clinuvel investigational siteClinuvel, Inc.

Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Spesolimab for Pyoderma Gangrenosum

This trial will study if spesolimab can help treat ulcers caused by pyoderma gangrenosum, an autoimmune skin condition, and how it affects the body's immune system.

Icahn School of Medicine at Mount SinaiSaakshi Khattri, MDBoehringer Ingelheim

Image of Anniston Medical Clinic in Anniston, United States.

Imvotamab for Rheumatoid Arthritis

This trial will test if a drug (imvotamab) is safe and tolerable in people with RA who have failed other treatments. Placebos will also be given.

No Cost For Treatment

Anniston Medical Clinic (+13 Sites)Rebecca KunderIGM Biosciences, Inc.

Image of Altoona Center For Clinical Research Site Number : 8400002 in Duncansville, United States.

SAR441566 for Rheumatoid Arthritis

Duncansville, PA

This trial is testing a new drug treatment for rheumatoid arthritis in adults not adequately controlled on methotrexate. It will include 8 visits over 12 wks to assess safety & efficacy.

Altoona Center For Clinical Research Site Number : 8400002 (+10 Sites)Clinical Sciences & OperationsSanofi

Have you considered Astagraf Xl clinical trials? We made a collection of clinical trials featuring Astagraf Xl, we think they might fit your search criteria.

Explore trials for Astagraf Xl

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security